BlackRock Fund Advisors recently announced the acquisition of new stake in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). The institutional investor has increased its shareholding in the Healthcare company by 14.99% to 5.1 million shares with purchase of 0.67 million shares. This fresh investment now brings its stake to 6.98% valued currently at $81.88 million. In addition, SSgA Funds Management, Inc. raised its holdings by 1.35 million to 4.6 million shares. And The Vanguard Group, Inc. has lifted its position by 9.32% or 0.29 million shares – to 3.36 million shares.

With over 1.22 million Karyopharm Therapeutics Inc. (KPTI) shares trading Tuesday and a closing price of $15.35 on the day, the dollar volume was approximately $18.68 million. The shares have shown a positive weekly performance of 5.28% and its price on 09/01/20 gained nearly 0.92%. Currently, there are 73.24M common shares owned by the public and among those 66.42M shares have been available to trade.

An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 10 analysts who have offered their price forecasts for KPTI have a consensus price objective of $32.00. The analysts have set the share’s price value over the next 12 months at a high of $41.00 and a low of $20.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Karyopharm Therapeutics Inc. stock is 1.70 for the next 12 months. But an upside of 62.56% will see the stock hit the forecast high price target while mean target price for the stock is $32.50.

Insiders at the company have transacted a total of 113 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 52 of these insider trades were purchases, accounting for 430,693 shares. Insider sales of the common stock occurred on 61 occasions, with total insider shares sold totaling 423,622 shares.

The top 3 mutual fund holders in Karyopharm Therapeutics Inc. are SPDR S&P Biotech ETF, Vanguard Total Stock Market Index, and iShares Russell 2000 ETF. SPDR S&P Biotech ETF owns 3.48 million shares of the company’s stock, all valued at over $55.82 million. The company sold 34839.0 shares recently to bring their total holdings to about 4.76% of the shares outstanding. Vanguard Total Stock Market Index sold 1882.0 shares to see its total holdings shrink to 1.75 million shares valued at over $28.04 million and representing 2.39% of the shares outstanding. iShares Russell 2000 ETF sold 67830.0 shares to bring its total holdings to over 1.45 million shares at a value of $23.27 million. iShares Russell 2000 ETF now owns shares totaling to 1.98% of the shares outstanding.

Shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) opened at $15.34, up $0.13 from a prior closing price of $15.21. However, the script later closed the day at $15.35, up 0.92%. The company’s stock has a 5-day price change of 5.28% and -12.78% over the past three months. KPTI shares are trading -19.93% year to date (YTD), with the 12-month market performance up to 84.94% higher. It has a 12-month low price of $8.02 and touched a high of $29.61 over the same period. Currently, 1.22 million shares have been traded, compared to an average intraday trading volume of 1.78 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 3.05%, -10.23%, and -16.05% respectively.

Institutional ownership of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) shares accounts for 91.03% of the company’s 73.24M shares outstanding. Mutual fund holders own 31.11%, while other institutional holders and individual stakeholders account for 66.29% and 17.26% respectively.

It has a market capitalization of $1.08B and a beta (3y monthly) value of 1.14. The earnings-per-share (ttm) stands at -$2.84. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.39% over the week and 4.60% over the month.

Analysts forecast that Karyopharm Therapeutics Inc. (KPTI) will achieve an EPS of -$0.69 for the current quarter, -$0.51 for the next quarter and -$1.71 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.82 while analysts give the company a high EPS estimate of -$0.37. Comparatively, EPS for the current quarter was -$0.67 a year ago. Earnings per share for the fiscal year are expected to decrease by -2.60%, and 34.00% over the next financial year.

If you are looking to buy this stock, then you may note that the average analyst recommendation by 10 brokerage firm advisors rate Karyopharm Therapeutics Inc. (KPTI) as a “Strong Buy” at a consensus score of 1.70. Specifically, 8 Wall Street analysts polled rate the stock as a buy, while 1 of the 10 advise that investors “hold,” and 0 rated it as a “Sell.”

Looking at the support for the KPTI, a number of firms have released research notes about the stock. Morgan Stanley stated their Overweight rating for the stock in a research note on July 02, 2020, with the firm’s price target at $34. Barclays coverage for the Karyopharm Therapeutics Inc. (KPTI) stock in a research note released on March 04, 2020 offered a Overweight rating with a price target of $30. Wedbush was of a view on January 17, 2020 that the stock is Neutral, while JP Morgan gave the stock Overweight rating on July 23, 2019, issuing a price target of $8- $16. Robert W. Baird on their part issued Outperform rating on July 05, 2019.